Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months.

Autor:	Sahay RR; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Yadav PD; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Nandapurkar A; Aundh Chest Hospital, Pimpri-Chinchwad, Pune, India., Dhawde R; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Suryawanshi A; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Patil DY; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Shete AM; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Sapkal GN; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Kulkarni M; Aundh Chest Hospital, Pimpri-Chinchwad, Pune, India., Gurav YK; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Deshpande GR; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Ghodke JS; Aundh Chest Hospital, Pimpri-Chinchwad, Pune, India., Jain R; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Hawale R; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Kalele K; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Yemul J; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Gawande P; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India., Abraham P; Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, India.
Jazyk:	angličtina
Zdroj:	Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 30; Vol. 18 (7), pp. 2156753. Date of Electronic Publication: 2022 Dec 28.
DOI:	10.1080/21645515.2022.2156753
Abstrakt:	We have evaluated the immunogenicity of two dose of Covaxin given at a one-month interval to two adult populations, i.e. COVID-19 naïve-vaccinated individuals (n = 118) and COVID-19 recovered individuals (n = 128) with the vaccination. The immune response in the study population were assessed at three follow-ups, namely at one month post first dose, one and six months after the second dose. The persistence of S1RBD IgG and neutralizing antibodies for six months post vaccination was observed at different time intervals. The enhanced immune response was observed in both the participant groups. The study emphasizes the need for a booster dose post six months of vaccination.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu